Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review

Gadolinium‐based contrast agents (CAs) are widely used to enhance the contrast of images in magnetic resonance imaging procedures. Two categories of gadolinium chelates exist: the macrocyclic molecules where Gd3+ is caged in the pre‐organized cavity of the ligand and the linear molecules. Gadolinium chelates differ in their thermodynamic stability constants and in their kinetic stability. In general, macrocyclic chelates such as Gd‐DOTA or Gd‐HP‐DO3A are more stable than linear molecules. Even among linear agents, differences can be found. There is increasing evidence that transmetallation can be found in vivo, in the case of certain CAs (especially linear chelates), with body cations such as zinc, calcium or iron. Furthermore, analytical interference with colorimetric determination of calcium has been clinically evidenced with two linear chelates, Gd‐DTPA‐BMA and Gd‐DTPA‐BMEA. Clinical cases of spurious hypocalcaemia have been reported with these molecules. Such interference with some colorimetric assays for calcium is clinically relevant in that it can lead to unnecessary and potentially harmful treatment for hypocalcaemia.

[1]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[2]  M. Tweedle,et al.  Comparison of Gd(DTPA-BMA) (Omniscan) Versus Gd(HP-DO3A) (ProHance) Relative to Gadolinium Retention in Human Bone Tissue by Inductively Coupled Plasma Mass Spectroscopy , 2006, Investigative radiology.

[3]  H. Ersoy,et al.  Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements , 2006, Journal of magnetic resonance imaging : JMRI.

[4]  V. Lorusso,et al.  Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as 'sponges' of Gd3+ ions. , 2006, Contrast media & molecular imaging.

[5]  Sandra F. Williams,et al.  Spurious hypocalcemia after gadodiamide administration. , 2005, Mayo Clinic proceedings.

[6]  P. Anelli,et al.  Magnetic resonance contrast agents: from the bench to the patient. , 2005, Current pharmaceutical design.

[7]  J. Mintorovitch,et al.  Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.

[8]  T. Ishiguchi,et al.  Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. , 2005, Radiation medicine.

[9]  T. Balzer,et al.  Interference of Gadolinium-Containing Contrast-Enhancing Agents With Colorimetric Calcium Laboratory Testing , 2005, Investigative radiology.

[10]  R. Oyen,et al.  Artifactual hypocalcaemia after intravenous administration of gadodiamide (Omniscan). , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  R. Natesh,et al.  Structure of angiotensin I-converting enzyme. , 2004, Cellular and molecular life sciences : CMLS.

[12]  U. Eriksson,et al.  What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.

[13]  M. Hynes,et al.  Measurement of serum calcium concentration after administration of gadoversetamide in dogs. , 2004, Radiology.

[14]  G. Kost,et al.  Spurious hypocalcemia after Omniscan- or OptiMARK-enhanced magnetic resonance imaging: an algorithm for minimizing a false-positive laboratory value. , 2004, Archives of pathology & laboratory medicine.

[15]  G. R. Stevens,et al.  Pharmacokinetics and Safety of the MRI Contrast Agent Gadoversetamide Injection (Optimark) in Healthy Pediatric Subjects , 2004, Investigative radiology.

[16]  W. Gibby,et al.  Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission Spectroscopy , 2004, Investigative radiology.

[17]  L. V. Rao,et al.  Gadolinium magnetic resonance contrast agents produce analytic interference in multiple serum assays. , 2004, American journal of clinical pathology.

[18]  N. Abdou,et al.  Safety assessment of gadoversetamide (OptiMARK®) administered by power injector , 2004, Journal of magnetic resonance imaging : JMRI.

[19]  Pseudohypocalcemia after magnetic resonance imaging with gadolinium in patients with cirrhosis , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  C. Corot,et al.  Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation , 1998, Biometals.

[21]  M. Knopp,et al.  More on pseudohypocalcemia and gadolinium-enhanced MRI. , 2004, The New England journal of medicine.

[22]  V. Runge,et al.  Contrast Agents for Magnetic Resonance Imaging: Safety Update , 2003, Topics in magnetic resonance imaging : TMRI.

[23]  C. J. Doorenbos,et al.  Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. , 2003, The New England journal of medicine.

[24]  M. Bellin,et al.  Currently used non-specific extracellular MR contrast media , 2003, European Radiology.

[25]  K. Kent,et al.  Gadodiamide administration causes spurious hypocalcemia. , 2003, Radiology.

[26]  A. Turner Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. , 2003, Biochemical Society transactions.

[27]  B. Rogachev,et al.  Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  Baker Rj The effect of gadolinium-based MRI contrast agents on the biodistribution of 67Ga , 2002 .

[29]  R. Baker The effect of gadolinium-based MRI contrast agents on the biodistribution of 67Ga , 2002, Nuclear medicine communications.

[30]  O. Wada,et al.  Increased apoptosis in a variety of tissues of zinc-deficient rats. , 2001, Life sciences.

[31]  M. Periasamy,et al.  Toxicological Assessment of Gadoversetamide Injection (OptiMARK®), a New Contrast-Enhancement Agent for Use in Magnetic Resonance Imaging , 2001, Investigative radiology.

[32]  S. Laurent,et al.  Stability of MRI Paramagnetic Contrast Media: A Proton Relaxometric Protocol for Transmetallation Assessment , 2001, Investigative radiology.

[33]  K Bensel,et al.  Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  C. Fierke,et al.  Function and mechanism of zinc metalloenzymes. , 2000, The Journal of nutrition.

[35]  W. Heindel,et al.  Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. , 2000, Investigative radiology.

[36]  A. Pałasz,et al.  Toxicological and cytophysiological aspects of lanthanides action. , 2000, Acta biochimica Polonica.

[37]  M. Port,et al.  Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. , 1999, Journal of pharmaceutical and biomedical analysis.

[38]  R. Lauffer,et al.  Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. , 1999, Chemical reviews.

[39]  H. Thomsen,et al.  Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. , 1998, Academic radiology.

[40]  C. Corot,et al.  Structure‐activity relationship of macrocyclic and linear gadolinium chelates: Investigation of transmetallation effect on the zinc‐dependent metallopeptidase angiotensin‐converting enzyme , 1998, Journal of magnetic resonance imaging : JMRI.

[41]  Krishan Kumar Macrocyclic polyamino carboxylate complexes of Gd(III) as magnetic resonance imaging contrast agents , 1997 .

[42]  W. Gibby,et al.  Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. , 1996, Investigative radiology.

[43]  J. Brunberg,et al.  Adverse reactions to gadolinium contrast media: a review of 36 cases. , 1996, AJR. American journal of roentgenology.

[44]  W. Gibby,et al.  Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. , 1996, Investigative radiology.

[45]  G. Jackson,et al.  Metal ion speciation in blood plasma: gallium-67-citrate and MRI contrast agents. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  H. Hakusui,et al.  Pharmacokinetics and stability of caldiamide sodium in rats. , 1996, Arzneimittel-Forschung.

[47]  P. Normann,et al.  Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. , 1995, Scandinavian journal of clinical and laboratory investigation.

[48]  P. Wedeking,et al.  Biodistribution of Radiolabeled, Formulated Gadopentetate, Gadoteridol, Gadoterate, and Gadodiamide in Mice and Rats , 1995, Investigative radiology.

[49]  H. Weinmann,et al.  Pharmacokinetics, Dose Proportionality, and Tolerability of Gadobutrol after Single Intravenous Injection in Healthy Volunteers , 1994, Investigative radiology.

[50]  E. Holtz,et al.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.

[51]  J. S. Mann,et al.  Stability of Gadolinium Complexes In Vitro and In Vivo , 1993, Journal of computer assisted tomography.

[52]  N. Obuchowski,et al.  3D MRI of the cervical spine: low flip angle FISP vs. Gd-DTPA TurboFLASH in degenerative disk disease. , 1993, Journal of computer assisted tomography.

[53]  A. Nordenbo,et al.  Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA , 1992, The Lancet.

[54]  M. Tweedle,et al.  Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. , 1992, Investigative radiology.

[55]  C. Higgins,et al.  Amelioration of cardiodepressive effects of gadopentetate dimeglumine with addition of ionic calcium. , 1992, Radiology.

[56]  W. Matthai,et al.  Comparative Safety of High‐Osmolality and Low‐Osmolality Radiographic Contrast Agents: Peport of a Multidisciplinary Working Group , 1992, Investigative radiology.

[57]  P. Wedeking,et al.  Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. , 1992, Magnetic resonance imaging.

[58]  S. Quay,et al.  A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. , 1991, Investigative radiology.

[59]  H. Weinmann,et al.  Gallium-67/stable gadolinium antagonism. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  H. Niendorf,et al.  Tolerance data of Gd-DTPA: a review. , 1991, European journal of radiology.

[61]  J. Hagan,et al.  Reaction of gadolinium chelates with endogenously available ions. , 1991, Magnetic resonance imaging.

[62]  D. White,et al.  Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[63]  B. Biagi,et al.  Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. , 1990, The American journal of physiology.

[64]  B. Bonnemain,et al.  Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. , 1990, Investigative radiology.

[65]  J. Lansman Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit , 1990, The Journal of general physiology.

[66]  W. Cacheris,et al.  The relationship between thermodynamics and the toxicity of gadolinium complexes. , 1990, Magnetic resonance imaging.

[67]  H. Niendorf,et al.  Serum iron and serum bilirubin after administration of Gd-DTPA-dimeglumine. A pharmacologic study in healthy volunteers. , 1988 .

[68]  J. Wittenberg,et al.  Gd-DOTA: characterization of a new paramagnetic complex. , 1988, Radiology.

[69]  P. Wedeking,et al.  Comparison of the biodistribution of 153Gd-labeled Gd(DTPA)2-, Gd(DOTA)-, and Gd(acetate)n in mice. , 1988, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[70]  E. Roux,et al.  Contrast agents in magnetic resonance imaging. , 1988, Journal belge de radiologie.

[71]  A. Prasad Clinical manifestations of zinc deficiency. , 1985, Annual review of nutrition.

[72]  N. Itoh,et al.  Characterization of Gd3+ and Tb3+ binding sites on Ca2+,Mg2+-adenosine triphosphatase of sarcoplasmic reticulum. , 1984, Journal of biochemistry.

[73]  J. C. Smith,et al.  Testicular damage associated with zinc deficiency in pre- and postpubertal rats: response to zinc repletion. , 1982, The Journal of nutrition.

[74]  Á. Párducz,et al.  Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. , 1980, British journal of experimental pathology.

[75]  L. Hurley,et al.  Severe zinc deficiency in male and female rats. , 1968, The Journal of nutrition.